Discovery of Covalent Ligands via Noncovalent Docking by Dissecting Covalent Docking Based on a "Steric-Clashes Alleviating Receptor (SCAR)" Strategy

Covalent ligands modulating protein activities/signals have attracted unprecedented attention in recent years, but the insufficient understanding of their advantages in the early days of drug discovery has hindered their rational discovery and development. This also left us inadequate knowledge on the rational design of covalent ligands, e.g., how to balance the contribution from the covalent group and the noncovalent group, respectively. In this work, we dissected the noncovalent docking from covalent docking by creating SCARs (steric-clashes alleviating receptors). We showed that the SCAR method outperformed those specifically developed but more complicated covalent docking protocols. We furthermore provided a "proof-of-principle" example by implementing this method in the first high-throughput screening and discovery of novel covalent inhibitors of S-adenosylmethionine decarboxylase. This work demonstrated that noncovalent groups play a predeterminate role in the design of covalent ligands, and would be of great value in accelerating the discovery and development of covalent ligands.

[1]  Kai Zhu,et al.  Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands , 2014, J. Chem. Inf. Model..

[2]  R. A. Bauer Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. , 2015, Drug discovery today.

[3]  Shuo Zhou,et al.  CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints , 2013, J. Comput. Chem..

[4]  K N Houk,et al.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.

[5]  Tudor I. Oprea,et al.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes , 2015, Cell.

[6]  R. Lilien,et al.  LigAlign: flexible ligand-based active site alignment and analysis. , 2010, Journal of molecular graphics & modelling.

[7]  Xiao Tan,et al.  Discovery of novel inhibitors of human S-adenosylmethionine decarboxylase based on in silico high-throughput screening and a non-radioactive enzymatic assay , 2015, Scientific Reports.

[8]  Luhua Lai,et al.  Nonnatural protein–protein interaction-pair design by key residues grafting , 2007, Proceedings of the National Academy of Sciences.

[9]  Robert Mah,et al.  Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[10]  Tanja Kortemme,et al.  Control of protein signaling using a computationally designed GTPase/GEF orthogonal pair , 2012, Proceedings of the National Academy of Sciences.

[11]  Jeffrey A. Nichols,et al.  Ionization Potential, Electron Affinity, Electronegativity, Hardness, and Electron Excitation Energy: Molecular Properties from Density Functional Theory Orbital Energies , 2003 .

[12]  Kai Zhu,et al.  Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..

[13]  Stefan G. Kathman,et al.  Covalent Tethering of Fragments For Covalent Probe Discovery. , 2016, MedChemComm.

[14]  Jens Meiler,et al.  ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.

[15]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[16]  Irwin D. Kuntz,et al.  Development and validation of a modular, extensible docking program: DOCK 5 , 2006, J. Comput. Aided Mol. Des..

[17]  S E Ealick,et al.  The structural basis for substrate specificity and inhibition of human S-adenosylmethionine decarboxylase. , 2001, Biochemistry.

[18]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[19]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[20]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[21]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[22]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[23]  Stefano Forli,et al.  Covalent docking using autodock: Two‐point attractor and flexible side chain methods , 2016, Protein science : a publication of the Protein Society.

[24]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[25]  Mahmoud E S Soliman,et al.  New drug design with covalent modifiers , 2016, Expert opinion on drug discovery.

[26]  Zukang Feng,et al.  The chemical component dictionary: complete descriptions of constituent molecules in experimentally determined 3D macromolecules in the Protein Data Bank , 2015, Bioinform..

[27]  António J. M. Ribeiro,et al.  Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. , 2013, Current medicinal chemistry.

[28]  G. S. Walker,et al.  Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. , 2014, Journal of medicinal chemistry.

[29]  W. Guida,et al.  New Insights into the Design of Inhibitors of Human S-Adenosylmethionine Decarboxylase: Studies of Adenine C8 Substitution in Structural Analogues of S-Adenosylmethionine† , 2009, Journal of medicinal chemistry.

[30]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[31]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[32]  Richard J. Marhöfer,et al.  Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. , 2013, Journal of medicinal chemistry.

[33]  Chao Tang,et al.  Reliable cell cycle commitment in budding yeast is ensured by signal integration , 2014, eLife.

[34]  F. Nan,et al.  Inhibition of monometalated methionine aminopeptidase: inhibitor discovery and crystallographic analysis. , 2007, Journal of medicinal chemistry.

[35]  Kay Hamacher,et al.  DOCKTITE - A Highly Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening in the Molecular Operating Environment , 2015, J. Chem. Inf. Model..

[36]  Feng Cong,et al.  Chemical genetics-based target identification in drug discovery. , 2012, Annual review of pharmacology and toxicology.

[37]  Nir London,et al.  Covalent Docking of Large Libraries for the Discovery of Chemical Probes , 2014, Nature chemical biology.

[38]  W. Guida,et al.  Role of the sulfonium center in determining the ligand specificity of human s-adenosylmethionine decarboxylase. , 2009, Biochemistry.

[39]  F. White,et al.  Using small molecules and chemical genetics to interrogate signaling networks. , 2011, ACS chemical biology.

[40]  Soumendranath Bhakat,et al.  Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls , 2015, Molecules.

[41]  Charlotte M. Deane,et al.  Freely Available Conformer Generation Methods: How Good Are They? , 2012, J. Chem. Inf. Model..